期刊
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
卷 183, 期 -, 页码 -出版社
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.ejmech.2019.111715
关键词
Polycomb repressive complex 2 (PRC2); Hydroxychloroquine (HCQ); Docking; Molecular dynamics simulations (MDs); Drug repurposing
资金
- Italian Association for Cancer Research (AIRC): Small molecule-based targeting of lncRNAs 3D structure: a translational platform for the treatment of multiple myeloma [21588]
- COST [CA15135]
- PRIN 2017 research project Novel anticancer agents endowed with multi-targeting mechanism of action [201744BN5T]
Multiple myeloma (MM) is an incurable hematological malignancy driven by several genetic and epigenetic alterations. The hyperactivation of the Polycomb repressive complex 2 (PRC2), a multi-subunit oncogenic histone methyltransferase, has been implicated in the pathogenesis of this malignancy. Upon protein-protein interaction (PPI) between the catalytic subunit EZH2 and EED, PRC2 primarily methylates lysine 27 of histone H3 (H3K27me3), thus modulating the chromatin structure and inducing transcriptional repression. Herein, we highlight a new mechanism of action that can contribute to explain the anti-tumor activity of hydroxychloroquine (HCQ), an anti-malaric agent also known as autophagy inhibitor. By structural studies, we demonstrate that HCQ inhibits the allosteric binding of PRO to EED within the H3K27me3-binding pocket, thus antagonizing the PRO catalytic activity. In silico results are compatible with the significant reduction of the H3K27me3 levels in MM cells exerted by HCQ Overall, these findings disclose a novel epigenetic activity of HCQ with potential implications for its clinical repositioning. (C) 2019 Elsevier Masson SAS. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据